1. Introduction {#heading-c40fa74e763552faa6af6347a3eda5a0}
===============

The worldwide morbidity and mortality rates attributed to multi-drug-resistant (MDR) pathogens have been increasing rapidly. According to the WHO, between 2011 and 2015 more than 2 million people have been diagnosed with MDR bacterial infections^[@R1065]^. In the case of MDR-*Mycobacterium tuberculosis* (MDR-TB), more than 25,000 diagnoses are confirmed each year^[@R1065]^. In addition, the emergence in 2010 of new MDR gram-negative Enterobacteriaceae with resistance to carbapenem, conferred by New Delhi metallo-β-lactamase 1 (NDM-1), was heralded as a potential major global health problem due to resistance to most if not all antibiotics^[@R1066]^. Recent outbreaks in Germany and other E.U. countries of Enterohaemorrhagic *E. coli*(EHEC O104:H4) bacteria that are resistant to a broad spectrum of antibiotics, as well as cases of haemolytic uraemic syndrome (HUS), have emphasized the urgent need for effective antibiotics for treatment of severe infections caused by MDR bacteria^[@R1067]^.

Previously, the molecular descriptors that determine long-range interactions between therapeutic molecules and their molecular targets, such as the electron-ion interaction potential (EIIP) and average quasi-valence number (AQVN)^[@R1068]^, were used for the discovery of potential new molecules with anti-HIV activities^[@R1070]^. Here, we have used these same molecular descriptors to analyze antibiotics for their potential use against MDR bacteria, such as NDM-1-positive *Enterobacteriaceae* and *E. coli*strainEHEC O104:H4. Based on results of this analysis, we have proposed a simple and general chemoinformatics criterion for selection of antibiotics that could be potentially effective for treatment of MDR bacteria.

2. Descriptors for Molecular Interactions {#heading-5615af8d22cf226df065aab5cfaa6519}
=========================================

The physical concept of using the EIIP and AQVN to describe molecular interactions was previously described in detail elsewhere^[@R1068]^. Here we will briefly present how calculation of the molecular descriptors (EIIP and AQVN) can be used for organic molecules, such as antibiotics, by the use of a simple equation derived from the "general model of pseudopotential"^[@R1073]^.

The molecular descriptor EIIP (W) is defined by the equation^[@R1073]^,

$\begin{document}
$$
W = 0.25 \frac{Z^ \star sin(1.04  \pi  Z^ \star ) }{2 \pi } 
$$
\end{document}
$ (1)

and Z\* is the average quasi-valence number (AQVN) determined by

$\begin{document}
$$
Z^ \star =  \frac{1}{N}   \sum_{i=1}^{m}{n_i Z_i} 
$$
\end{document}
$ (2)

where Z*i*is the valence number of the *i*-th atomic component, *n~i~*is the number of atoms of the *i*-th component, *m*is the number of atomic components in the molecule, and N is the total number of atoms.

The EIIP values can be calculated according to equations (1) and (2) in Rydbergs (Ry).

3. Results Using Molecular Descriptors EIIP and AQVN {#heading-3be4224de6a6760527240ebc7837ef22}
====================================================

A strong connection between EIIP and AQVN calculated for organic molecules and their biological activities (mutagenicity, carcinogenicity, toxicity as well as antibiotic, cytostatic and anti-HIV activities) has been demonstrated (for reviews, see references^[@R1068]^). It was shown that these biological activities, which are usually conferred by the ability of a molecule or its metabolites to interact covalently or non-covalently with various cellular or extra-cellular targets, are influenced by molecular electronic properties, such as EIIP and AQVN, that determine long-range intermolecular interactions^[@R1068]^.

Of important note is that the molecular descriptors that we have described above do not depend on knowing precise molecular structures (see Equations \[1\] and \[2\]). This suggests that long-distance recognition and targeting between interacting molecules are structurally invariant. Thus, the EIIP and AQVN are parameters, among over 3,300 molecular descriptors, that are currently being used for characterization of organic molecules^[@R1069]^. These parameters can describe potential long-range molecular interaction properties of molecules.

Here we have used the EIIP and AQVN parameters for analysis of different antibiotic classes and individual antibiotics for MDR *Enterobacteriaceae* and *E. coli*strainEHEC O104:H4. In order to determine the range of molecular descriptors for each of the antibiotic classes that we analyzed, we have presented the values of EIIP and AQVN calculated for 230 penams, cephems, carbapenems and penems, monobactams, β-lactamase inhibitors, quinolones, aminoglycosides, ansamycins, tetracyclines, macrolides, pleuromutilins, sulfonamides, rifamycins, lincosamides, glycopeptides, nitromidizoles, oxazolidinones, lipopeptides, streptogramins and nitrofurans, among other possible antibiotics (Supplementary Table 1). The ranges of EIIP and AQVN descriptors, which encompass \>85% of the antibiotics of each analyzed class, are shown in**[Table 1](#table-wrap-70fb2d4aefc4003f202b36240ab7147b){ref-type="table"}**. In order to locate the positions of the analyzed antibiotics in the chemical spaces represented by EIIP and AQVN, we have compared the calculated molecular descriptors with the same molecular descriptors calculated for 45,010,644 compounds from the PubChem database (http://www.ncbi.nlm.nih.gov/pccompound).

As shown in**[Figure 1](#fig-78f2d890ce31d20dfe097baf17147172){#xref-542a4f1fb90473efe0bd4039e1a0bce4 ref-type="fig"}**, 92.5% of the compounds from the PubChem database are homogenously distributed within EIIP and AQVN intervals 0.00 -- 0.11 Ry and 2.4 -- 3.3, respectively. This domain of the EIIP/AQVN space, encompassing the majority of known chemical compounds, will be further referred to as the "basic EIIP/AQVN chemical space" (BCS). In**[Figure 1](#fig-78f2d890ce31d20dfe097baf17147172){#xref-3e36f7e640fe4cbf42727f64a59d2028 ref-type="fig"}** (b) the distribution of EIIP and AQVN values of the antibiotics from Supplementary Table 1 are shown. Note that the overwhelming majority of analyzed antibiotics (94.3%) are located within the BCS.

![Distribution of EIIP and AQVN values\
calculated for (a) 44,987,581 compounds from PubChem database, (b) antibiotics presented in Supplementary Table 1, and (c) antibiotics for which NDM-1-positive Entero-bacteriaceae isolated in Great Britain and India are resistant^2^.](discoveries-04-064-g001){#fig-78f2d890ce31d20dfe097baf17147172}

table-wrap-70fb2d4aefc4003f202b36240ab7147b

###### Ranges of AQVN and EIIP that are characteristic for particular antibiotic classes

  ---------------------- ---------------- ----------------
  Antibiotic class       AQVN             EIIP \[Ry\]
  Penicillins            2.975 -- 3.180   0.035 -- 0.124
  Cephalosporins         3.071 -- 3.473   0.070 -- 0.130
  Carbapenems & Penems   2.973 -- 3.059   0.022 -- 0.066
  Monobactams            3.166 -- 3.581   0.100 -- 0.134
  Quinolines             2.760 -- 3.060   0.003 -- 0.065
  Aminoglycosides        2.552 -- 2.820   0.024 -- 0.084
  Tetracyclines          2.933 -- 3.111   0.018 -- 0.084
  Macrolides             2.467 -- 2.630   0.077 -- 0.096
  Pleuromutilins         2.395 -- 2.473   0.095 -- 0.096
  Nitrofurans            3.652 -- 3.826   0.010 -- 0.086
  ---------------------- ---------------- ----------------

4. Discussion {#heading-10373624a9749ff3ca0856d2cba3ec56}
=============

Previously we demonstrated that the specific AQVN/EIIP domains combined with the structural properties of molecules can be used as a possible filter for the virtual screening of molecular libraries for new active drug candidates^[@R1068]^. Accordingly, the AQVN/EIIP intervals presented in**[Table 1](#table-wrap-70fb2d4aefc4003f202b36240ab7147b){ref-type="table"}**, representing the chemoinformatic "fingerprints" of various antibiotic classes, can be used for the virtual screening of molecular databases for new candidate antibiotics. Once new possible antibiotic candidates are identified, traditional methods can be used to confirm their usefulness. Thus, expensive testing on thousands of potential new antibiotics could be reduced to manageable numbers.

The approach described here can also be used to identify potential new antibiotics that can overcome the problem of antibiotic resistance. For example, the EIIP and AQVN values can be calculated for antibiotics useful for treatment of resistant NDM-1-positive *Enterobacteriaceae* isolated in Great Britain and in North (Chennai) and South (Haryana) India (**[Table 2](#table-wrap-5e1f98f94619c26fa3dde3b8b541990f){ref-type="table"}**). In this example, the 'resistant' antibiotics are distributed within EIIP and AQVN ranges of 0.00 -- 0.13 Ry and 2.55 -- 3.42, respectively. As shown in**[Figure 2](#fig-8392c38ba3c33f83d342fd7e4d703138){#xref-19b6bcc27cad288e05b5856f2a5ca14d ref-type="fig"}**, these antibiotics cover the EIIP/AQVN area or domain of nearly all analyzed antibiotic classes, with the exception of pleuromutilins and nitrofurans. Therefore, the results presented in **[Figure 1](#fig-78f2d890ce31d20dfe097baf17147172){#xref-7abaf34e17a687fd0ad06670761be677 ref-type="fig"}**(b, c) and**[Figure 2](#fig-8392c38ba3c33f83d342fd7e4d703138){#xref-e05d2cf993074b0afb1bc8e450896f2a ref-type="fig"}**suggest that pleuromutilins and nitrofurans could be potentially useful antibiotics for overcoming the problem of antibiotic-resistance in NDM-1-positive Enterobacteriacea.

![The EIIP/AQVN domains of major antibiotic classes.\
Each of presented domains encompasses \>85% compounds belonging to the particular antibiotic class (black, penicillins; green, cephalosporins; gray, carbapenems and penems; magenta, quinolines; yellow, aminoglycosides; red, tetracyclines; olive, macrolides; royal, nitrofurans; purple, pleuromutilins; wine, sulfonamides. Open circles identify antibiotics for which NDM-1-positive Enterobacteriaceae isolated in Great Britain and North (Chennai) and South (Haryana) India are resistant.](discoveries-04-064-g002){#fig-8392c38ba3c33f83d342fd7e4d703138}

table-wrap-5e1f98f94619c26fa3dde3b8b541990f

###### Antibiotic susceptibilities for NDM-1-positive Enterobacteriaceae isolated in the UK and North and South India^[@R1066]^

  --------------- ------------------------ -------- ------------- ----------------
  Antibiotic      Chemical Formula         AQVN     EIIP \[Ry\]   Susceptibility
  Imipenem        C~12~H~17~N~3~O~4~S      2.973    0.0337        0%
  Meropenem       C~17~H~25~N~3~O~5~S      2.8235   0.0223        3%
  Piperacillin    C~23~H~27~N~5~O~7~S      3.0476   0.0616        0%
  Cefotaxime      C~16~H~17~N~5~O~7~S~2~   3.4043   0.1344        0%
  Ceftazidime     C~22~H~22~N~6~O~7~S~2~   3.2881   0.1267        0%
  Cefpirome       C~22~H~22~N~6~O~5~S~2~   3.193    0.1074        0%
  Aztreonam       C~13~H~17~N~5~O~8~S~2~   3.4222   0.1338        8%
  Ciprofloxacin   C~17~H~18~FN~3~O~3~      2.8571   0.0102        8%
  Gentamicin      C~21~H~43~N~5~O~7~       2.5526   0.0898        3%
  Tobramycin      C~18~H~37~N~5~O~9~       2.7246   0.0541        0%
  Amikacin        C~22~H~43~N~5~O~13~      2.8193   0.0238        0%
  Minocycline     C~23~H~27~N~3~O~7~       2.9333   0.0185        0%
  Tigecycline     C~29~H~39~N~5~O~8~       2.8148   0.0253        56%-67%
  --------------- ------------------------ -------- ------------- ----------------

We can also compare the AQVN and EIIP descriptors calculated for 25 antibiotics that are in pre-clinical and clinical development for use against MDR bacteria (**[Table 3](#table-wrap-60b0220deedb10923f5a11e8540b3682){ref-type="table"}**)^[@R1076]^.

table-wrap-60b0220deedb10923f5a11e8540b3682

###### Antibiotics against multidrug-resistant bacteria in pre-clinical and clinical development^[@R1076]^

  --------------- ----------------------------- ------- -------------
  Compound        Formula                       AQVN    EIIP \[Ry\]
  Ceftaroline     C~24~H~25~N~8~O~10~PS~4~      3.472   0.1298
  Telavancin      C~80~H~106~Cl~2~N~11~O~27~P   2.863   0.0079
  Oritavancin     C~86~H~97~Cl~3~N~10~O~26~     2.928   0.0164
  Dalbavancin     C~88~H~100~Cl~2~N~10~O~28~    2.947   0.0239
  Iclaprim        C~19~H~22~N~4~O~3~            2.833   0.0188
  Ceftobiprole    C~20~H~22~N~8~O~6~S~2~        3.276   0.1248
  Amadacycline    C~21~H~18~N~2~O~5~S           3.149   0.0952
  Delafloxacin    C~18~H~12~ClF~3~N~4~O~4~      3.143   0.0934
  Nemonoxacin     C~20~H~25~N~3~O~4~            2.769   0.0406
  Radezolid       C~22~H~23~FN~6~O~3~           2.909   0.0092
  PZ-601          C~18~H~21~N~3~O~4~S~2~        3       0.0439
  NXL 103         C~50~H~63~N~9~O~10~           2.788   0.0345
  Torezolid       C~17~H~15~FN~6~O~3~           3.143   0.0934
  WCK-771         C~19~H~21~FN~2~O~4~           2.808   0.0275
  Zabofloxacin    C~19~H~20~FN~5~O~4~           2.98    0.0362
  CEM-101         C~43~H~60~FN~6~O~10~          2.692   0.0631
  BC-3205         C~32~H~51~N~2~O~5~S           2.472   0.0959
  RWJ-416457      C~18~H~20~FN~5~O~3~           2.894   0.0034
  Platensimycin   C~24~H~27~NO~7~               2.881   0.0012
  PMX-30063       C~35~H~46~F~2~N~8~O~8~S       2.82    0.0235
  APN-1252        C~22~H~23~N~3~O~3~            2.824   0.0223
  NXL 104         C~25~H~31~FN~2~O~4~S~2~       2.738   0.0501
  ACHN-490        C~15~H~20~FN~5~O~4~           2.889   0.0016
  FR 264205       C~25~H~29~F~2~Cl~3~N~6~O~2~   2.627   0.078
  BAL-30072       C~46~H~63~N~6~O~15~PS         2.864   0.0078
  --------------- ----------------------------- ------- -------------

Only two compounds from this list (ceftaroline and BC-3205) have AQVN and EIIP values outside of the plotted domain in**[Figure 2](#fig-8392c38ba3c33f83d342fd7e4d703138){#xref-e5d036280ab3d5c5a0278b3c0661b82a ref-type="fig"}** that encompasses NDM-1 resistance, suggesting that antibiotics listed in**[Table 3](#table-wrap-60b0220deedb10923f5a11e8540b3682){ref-type="table"}**, which are potentially effective against NDM-positive bacteria, could be identified in advance of clinical testing. We are not suggesting that antibiotics that do not meet the criteria of AQVN and EIIP descriptors should not be tested. We are suggesting that antibiotics that meet these criteria should be considered a testing priority.

Recently data on the sensitivities of antibiotics against the novel pathogenic *Escherichia coli* strain EHEC O104:H4, which caused a severe outbreak in Germany in May 2011, have been reported^[@R1067]^. Using MDR strain EHEC O104:H4 bacteria the EIIP/AQVN descriptors have been calculated for various antibiotics that are listed in**[Table 4](#table-wrap-2f87228673c992077f80f8b3c63df592){ref-type="table"}**and shown as a domain plot in**[Figure 3](#fig-d5c95c7f734c3a9f7ee9b9e63878153f){#xref-ff7426aa80926ddd5b514b2aa923a56a ref-type="fig"}**. These data suggest that strain EHEC O104:H4 is sensitive to antibiotics with AQVN \<2.9 and EIIP in the range of 0.01-0.10. Thus, the data suggest that MDR bacterial strain EHEC O104:H4 should be resistant to antibiotics outside of this AQVN and EIIP domain. Some exceptions to this rule, however, have been found: chloramphenicol, fosfomycin, imipenem and nitrofurantin. In addition, the data suggest that aminoglycosides, macrolides and pluromutilins could be highly effective against the pathogenic *Escherichia coli* strain EHEC O104:H4.

![Distribution of AQVN and EIIP values of antibiotics tested against E. coli stain EHEC O104:H4^[@R1067]^\
(solid symbols, S=sensitive; open symbols, R=resistant).](discoveries-04-064-g003){#fig-d5c95c7f734c3a9f7ee9b9e63878153f}

table-wrap-2f87228673c992077f80f8b3c63df592

###### Antibiotic resistance and molecular descriptors AQVN and EIIP of *E. coli*strain EHEC O104:H4

  ------------------------------ ------------- --------------- --------------------
  Antibiotic                     AQVN          EIIP \[Ry\]     Resistance \[x\]\*
  Amoxicillin/Clavulanic acid    3.045/3.304   0.0608/0.1289   R
  Cefuroxim                      3.422         0.138           R
  Piperacillin/Sulbactam         3.048/3.231   0.0616/0.1163   R
  Tetracyclin                    3.036         0.0572          R
  Cefotaxim                      3.404         0.1344          R
  Ceftazidim                     3.288         0.1267          R
  Trimethoprim/Sulfamethoxazol   2.872/3.214   0.0048/0.1126   R
  Amikacin                       2.819         0.0238          S
  Ciprofloxacin                  2.875         0.0102          S
  Tobramycin                     2.725         0.0541          S
  Chloramphenicol                3.062         0.0669          S
  Fosfomycin                     3.2           0.1092          S
  Gentamicin                     2.553         0.0898          S
  Imipenem                       2.973         0.0337          S
  Kanamycin                      2.816         0.0264          S
  Meropenem                      2.824         0.0223          S
  Nalidixic acid                 3.034         0.0568          R
  Nitrofurantoin                 3.826         0.01            S
  Norfloxacin                    2.829         0.0202          S
  Piperacillin/Tazobactam        3.048/3.375   0.0616/0.1342   R
  Streptomycin                   2.911         0.0101          R
  Ampicillin                     2.977         0.0351          R
  Cefoxitin                      3.333         0.1319          R
  Cefpodoxim                     3.333         0.1319          R
  Cefuroxim-Axetil               3.422         0.1338          R
  ------------------------------ ------------- --------------- --------------------

Additionally, we found that the AQVN/EIIP domain of the NDM-1-containing antibiotic-resistant EHEC O104:H4 strain is broader than the corresponding domain found for EHEC O104:H4 strains that do not carry the NDM-1 gene. This suggests that acquisition of the NDM-1 gene by *Escherichia coli* EHEC O104:H4 could allow the selection of an appropriate antibiotic treatment against this highly pathogenic bacterial strain. For example, using the data presented in [Table 5](#table-wrap-9bc35348d63a161ab1d82eadf6bac76c){ref-type="table"}, there are two groups of antibiotics whose AQVN and EIIP descriptors are outside of the domain corresponding to the antibiotic resistance of the NDM-1-positive Enterobacteriacea and *Escherichia coli* strain EHEC O104:H4. These outlying antibiotics should be considered as therapeutic candidates for treatment of these MDR bacteria. It is of note that both groups of antibiotics are located outside the BCS and represent strong electron-donors (group A) and electron-acceptors (group B)^[@R1073]^. Thus, therapies that include combinations of antibiotics from group A and B could have a greater potential for success, because simultaneous presentation of toxic compounds with significantly different electronic properties could represent an insurmountable problem for these bacteria. As a corollary, analysis of the AQVN and EIIP descriptors of antibiotics presented here suggest that: (i) pleuromutilins and nitrofurans could be effective against NDM-1-positive Enterobacteriacea; (ii) aminoglycosides, macrolides and pluromutilins (and possibly nitrofurans) could be suitable for treatment of the novel highly pathogenic *E. coli* strain EHEC O104:H4; and (iii) a combination of antibiotics from groups A and B could be considered as a therapeutic option for the treatment of multi-drug resistant bacterial infections (**[Table 5](#table-wrap-9bc35348d63a161ab1d82eadf6bac76c){ref-type="table"}**). These single and combination antibiotics need to be further evaluated for their treatment potentials against MDR bacterial strains.

table-wrap-9bc35348d63a161ab1d82eadf6bac76c

###### Potential antibiotics for treatment of MDR bacteria selected according to the AQVN/EIIP criterion.

  ---------------- -------------------------- ------- -------------
  Group I          Formula                    AQVN    EIIP \[Ry\]
  Cefpodoxime      C~15~H~17~N~5~O~6~S~2~     3.333   0.132
  Tiamulin         C~28~H~47~NO~4~S           2.395   0.095
  Retapamulin      C~30~H~47~NO~4~S           2.434   0.096
  Valnemulin       C~31~H~52~N~2~O~5~S        2.44    0.096
  Azithromycin     C~38~H~72~N~2~O~12~        2.468   0.096
  BC-3205          C~32~H~51~N~2~O~5~S        2.472   0.096
  Group II                                            
  Ceftibuten       C~15~H~14~N~4~O~6~S~2~     3.463   0.131
  Ceftaroline      C~24~H~25~N~8~O~10~PS~4~   3.472   0.13
  Nifuroxazide     C~12~H~9~N~3~O~5~          3.517   0.123
  Ceftriaxone      C~18~H~18~N~8~O~7~S~3~     3.518   0.123
  Cefazolin        C~14~H~14~N~8~O~4~S~3~     3.535   0.12
  Tigemonam        C~12~H~15~N~5~O~9~S~2~     3.581   0.108
  Furazolidone     C~8~H~7~N~3~O~5~           3.652   0.086
  Nitrofurazone    C~6~H~6~N~4~O~4~           3.7     0.068
  Nifurtoinol      C~9~H~8~N~4~O~6~           3.704   0.066
  Nifurzide        C~12~H~8~N~4~O~6~S         3.806   0.02
  Nitrofurantoin   C~8~H~6~N~4~O~5~           3.826   0.01
  ---------------- -------------------------- ------- -------------

Bullet Points {#heading-be33179b6c3b7cb11f5fda347d2ccfd2}
=============

**◊ There is an urgent need for new antibiotics to treat MDR bacterial infections**

**◊ We describe a simple set of chemoinformatic molecular descriptors based on characteristics of electron donor and acceptor properties to select new candidate antibiotics**

**◊ Using these molecular descriptors we have suggested appropriate antibiotics that could be suitable for treatment of the highly pathogenic, multi-drug-resistant bacteria**
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